Atopic Dermatitis: Treating Beyond What You See

For many clinicians, escalation in AD isn’t tied to a single threshold anymore. It’s a judgment call, shaped by what the disease is doing over time and how much it’s affecting the patient’s day-to-day life. As familiarity with biologics has grown, along with reassuring safety data and broader indications, there’s been a noticeable shift toward earlier use, particularly with therapies targeting type 2 inflammation. This portion of the Biologics Innovation Experience examines how that shift is playing out in practice and the ways it’s changing when and how we intervene.